Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection

NCT03399903 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

47

Enrollment

OTHER

Sponsor class

Conditions

HIV-1-infection
Gut Inflammation

Interventions

DRUG: Pentasa vs Align

Sponsor

AIDS Healthcare Foundation

Collaborators

[object Object]